Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell, protein and combination therapeutics for underserved medical conditions. Stemedica has developed a proprietary manufacturing technology platform that produces allogeneic progenitor cell products with intellectual property protection under a low-oxygen, low-tension environment in a cGMP-compliant manufacturing facility. The company's lead drug candidate, ischemia-tolerant mesenchymal stem cells, or itMSCs, is an allogeneic progenitor cell therapy currently in clinical development for the treatment of COVID-19, ischemic stroke and Alzheimer's disease.
Looking for a particular Stemedica Cell Technologies employee's phone or email?
Stemedica Cell Technologies Questions
The Stemedica Cell Technologies annual revenue was $23.4 million in 2026.
Alexei Lukashev is the Director of Laser Stem Cell of Stemedica Cell Technologies.
4 people are employed at Stemedica Cell Technologies.
Stemedica Cell Technologies is based in San Diego, California.
The NAICS codes for Stemedica Cell Technologies are [5417, 54, 541713, 54171, 541].
The SIC codes for Stemedica Cell Technologies are [873, 87].
Top Stemedica Cell Technologies Employees
-
32
-
Kenneth Berger
Senior Director, Regulatory Affairs at Stemedica Cell Technologies
Newport Beach, CA, US15+ -
35+
Related Companies
